In het nieuws

December 2015

Arthrogen selected the Center for Human Drug Research (CHDR) in Leiden to execute the first clinical trial with Arthrogen’s lead product ART-I02 in the course of the second half of 2016.

November 2015

Today Arthrogen was honoured to welcome a visiting delegation of the Japanese Health Science Foundation. Arthrogen's Dr. Lisette Bevaart and Dr. Susanne Snoek presented the exciting Arthrogen program.

November 2015

Today Arthrogen presented at the Bio-Europe 2015 conference in Münich. Arthrogen's COO Dr. Janneke Meulenberg presented our ART-I02 gene therapy product and its clinical trial program.

November 2015

Arthrogen to present at the Bio Europe 2015 conference, November 2-4 in Munich, in the category Advanced Therapies/Regenerative Medicines.

Oktober 2015

Article in AMC Magazine. read more

September 2015

Arthrogen invited for two presentations at the ESGCT, one poster and one oral presentation.

June 2015

Preclinical Potency and Biodistribution Studies of an AAV 5 Vector Expressing Human Interferon-β (ART-I02) for Local Treatment of Patients with Rheumatoid Arthritis. read more

June 2015

Safety, Biodistribution, and Efficacy of an AAV-5 Vector Encoding Human Interferon-Beta (ART-I02) Delivered via Intra-Articular Injection in Rhesus Monkeys with Collagen-Induced Arthritis. read more

May 2015

Arthrogen presented at the ASGCT in New Orleans.